当前位置: 首页 > 期刊 > 《中国当代医药》 > 2016年第13期
编号:12859171
糖尿病患者神经肽Y的研究进展(4)
http://www.100md.com 2016年5月5日 《中国当代医药》 2016年第13期
     [15] Matyal R,Sakamuri S,Wang A,et al.Local infiltration of neuropeptide Y as a potential therapeutic agent against apoptosis and fibrosis in a swine model of hypercholesterolemia and chronic myocardial ischemia[J].Eur J Pharmacol,2013,718(1-3):261-270.

    [16] Zoccalic C,Mallamaci F,Tripepi G,et al.Prospective study of neuropeptide Y as an adverse cardiovascular risk factor in end-stage renal disease[J].J Am Soc Nephrol,2003, 14(10):2611-2617.

    [17] Ilhan A,Rasul S,Dimitrov A,et al.Plasma neuropeptide Y levels differ in distinct diabetic conditions[J].Neuropeptides,2010,44(6):485-489.

    [18] Ruipan Z,Xiangzhi M,Li L,et al.Differential expression and localization of neuropeptide Y peptide in pancreatic islet of diabetic and high fat fedrats[J].Peptides,2014,54(7):33-38.

    [19] Tomlison DR,Fernyhough P,Diemel LT.Role of neurotrophinsin diabetic neuropathyand treatmentwith nerve growth factors[J].Diabetes,1997,46(2):S43-S49.

    [20] Axelrod DA,UGR Jr,Demonner S,et al.Perioperative cardiovascular risk stratification of patients with diabetes who undergo elective major vascular surgery[J].J Vasc Surg,2002,35(5):894-901.

    (收稿日期:2016-02-17 本文编辑:王红双), http://www.100md.com(王利平 郭政)
上一页1 2 3 4